ライフサイエンスコーパス: 99mTc-sestamibi

1 rformed at 15 min and 2 hr after intravenous 99mTc-sestamibi.

2 racer and compare the results with those for 99mTc-sestamibi.

3 n be provided by an intravenous injection of 99mTc-sestamibi.

4 possible and as reliable as gated SPECT with 99mTc-sestamibi.

5 gated SPECT with 201Tl and gated SPECT with 99mTc-sestamibi.

6 nd at 1 hr postinjection of 925 MBq (25 mCi) 99mTc-sestamibi.

7 enone was much higher than the extraction of 99mTc-sestamibi (0.84 +/- 0.05 vs. 0.48 +/- 0.10, respec

8 Q4, 0.61 and 0.41; 99mTc-Q12, 0.63 and 0.39; 99mTc-sestamibi, 0.62 and 0.34; 99mTc-tetrofosmin, 0.68

9 erfusion data were obtained using a standard 99mTc-sestamibi 1-d imaging protocol.

10 201TI (111-167 MBq, 35 s/projection)-stress 99mTc-sestamibi (925-1480 MBq, 25 s/projection) separate

11 imaging agents have been developed, such as 99mTc-sestamibi, 99mTc-tetrofosmin and 99mTc-furifosmin.

12 usion agents (99mTc-Q3, 99mTc-Q4, 99mTc-Q12, 99mTc-sestamibi, 99mTc-tetrofosmin and 99mTcN-NOET) and

13 philic cationic radiopharmaceuticals such as 99mTc-sestamibi, 99mTc-tetrofosmin and 99Tc-furifosmin (

14 gle-photon-emission computed tomography with 99mTc-sestamibi, a membrane-permeant radiopharmaceutical

15 olesterol trafficking and the net content of 99mTc-Sestamibi, a reporter of drug transport activity m

16 [99mTc]Sestamibi, a P-glycoprotein transport substrate, i

17 Differential [99mTc]Sestamibi accumulation based upon P-glycoprotein e

18 inistration of the reversal agent increased [99mTc]Sestamibi accumulation in the xenografts expressin

19 A good correlation existed between tissue 99mTc sestamibi activity determined through well countin

20 Myocardial 99mTc-sestamibi activity correlated with flow when flow

21 Myocardial 99mTc-sestamibi activity correlates well with the extent

22 A 55% threshold of 99mTc-sestamibi activity had positive and negative predi

23 yocardial blood flow and relative myocardial 99mTc-sestamibi activity in the presence of a single-ves

24 In addition, relative myocardial 99mTc-sestamibi activity underestimated microsphere flow

25 0 micrograms/kg/min) dobutamine infusion and 99mTc-sestamibi administration.

26 aphy imaging studies using 201Tl at rest and 99mTc-sestamibi after adenosine stress.

27 99mTc sestamibi and 201 Tl are tracers that allow equiva

28 Myocardial perfusion imaging with 99mTc sestamibi and measurement of serum cardiac troponi

29 Relationships between 99mTc-sestamibi and 201Tl RRFs and microsphere RRFs were

30 ed with MRFP and radionuclide SPECT imaging (99mTc-sestamibi and 201Tl).

31 chnetate/sestamibi subtraction, double-phase 99mTc-sestamibi and 99mTc-sestamibi SPECT imaging to loc

32 ve much lower heart uptake (<0.6% ID/g) than 99mTc-Sestamibi ( approximately 18% ID/g) at >30 min p.i

33 Hepatobiliary and renal clearance of 99mTc-sestamibi are Pgp-mediated, and inhibition of Pgp

34 These observations show that [99mTc]Sestamibi as capable of detecting the modulation o

35 ntation received an intravenous injection of 99mTc sestamibi at 1 to 6 hours before transplantation.

36 s approximately 40 times better than that of 99mTc-Sestamibi at 120 min postinjection.

37 Tomographic imaging with 99mTc sestamibi before reperfusion and again 5 to 7 days

38 As an adjunct to current procedures, 99mTc-sestamibi breast imaging may contribute to patient

39 nstitutional sensitivity and specificity for 99mTc-sestamibi breast imaging were 75.4% and 82.7%, res

40 agnoses to define the diagnostic accuracy of 99mTc-sestamibi breast imaging.

41 Scintimammography with 99mTc-sestamibi can be used as a complementary technique

42 size and severity of myocardial defects from 99mTc sestamibi cardiac phantom studies performed on mul

43 he full clinical significance of EGBR during 99mTc-sestamibi cardiac imaging is a topic for future re

44 igate the frequency of EGBR during different 99mTc-sestamibi cardiac imaging, 1405 consecutive 99mTc-

45 ormance of attenuation-corrected (AC) stress 99mTc-sestamibi cardiac single-photon emission computed

46 ies to detect hibernating myocardium include 99mTc-sestamibi, contrast echocardiography, nuclear magn

47 ude mice was evaluated to determine whether [99mTc]Sestamibi could detect in vivo differences in P-gl

48 .2% for delayed 201Tl and 42.7 +/- 14.2% for 99mTc-sestamibi defects in these patients (p = NS).

49 .6% for delayed 201Tl and 44.5 +/- 11.3% for 99mTc-sestamibi defects.

50 .1% for delayed 201Tl and 67.7 +/- 12.4% for 99mTc-sestamibi defects.

51 r yet to be determined factors may influence 99mTc-sestamibi detectability in addition to tumor size.

52 In rats, pharmacokinetic analysis with 99mTc-sestamibi determined the concentration gradient to

53 her flow ranges (1.0 ml/min/g-3.5 ml/min/g), 99mTc-sestamibi did not track flow.

54 control rats was shown clearly, with uniform 99mTc-sestamibi distribution and 100% TTC staining for v

55 All patients received 20-30 mCi of 99mTc-sestamibi followed by SPECT imaging.

56 thickening to analogous values obtained from 99mTc-sestamibi gated perfusion SPECT (gated MIBI).

57 Myocardial gated SPECT with 99mTc-sestamibi has been used to quantify left ventricul

58 Mammoscintigraphy with 99mTc-sestamibi has high specificity and adequate sensit

59 nal quantitation of perfusion from 201Tl and 99mTc-sestamibi images is feasible and reproducible.

60 of ischemia-reperfusion (IR) and to compare 99mTc-sestamibi imaging and triphenyltetrazolium chlorid

61 ect on accumulation of 99mTc-Q complexes and 99mTc-sestamibi in KB-8-5 cells.

62 hese organs can be successfully imaged using 99mTc-sestamibi in patients.

63 yocardial perfusion imaging is compared with 99mTc-sestamibi in the diagnosis of coronary artery dise

64 multicenter trial the diagnostic accuracy of 99mTc-sestamibi in women with suspected breast cancer an

65 Two hours after 99mTc-sestamibi injection (5-10 mCi [185-370 MBq]), imag

66 Hearts were excised 20 min after 99mTc-sestamibi injection for SPECT imaging and post-mor

67 We studied 66 patients who received 20 mCi 99mTc-sestamibi intravenously.

68 125I-iodorotenone were greater than those of 99mTc-sestamibi, making 125I-iodorotenone the superior f

69 Preoperative tomographic 99mTc-sestamibi (MIBI) scintography and intraoperative m

70 ed for rest-stress electrocardiography-gated 99mTc-sestamibi MPS with AC were considered.

71 Ejection fractions computed from 99mTc-sestamibi myocardial perfusion gated tomograms hav

72 ft ventricular ejection fraction (LVEF) from 99mTc-sestamibi myocardial perfusion imaging studies.

73 ences in myocardial defect detection between 99mTc-sestamibi myocardial SPECT images reconstructed us

74 t on 125I-iodorotenone net retention than on 99mTc-sestamibi net retention 1 min after tracer injecti

75 -iodorotenone was significantly greater than 99mTc-sestamibi net retention at 1 min (0.77 +/- 0.08 vs

76 Rest thallium-201 and exercise 99mTc-sestamibi or 99mTc-tetrofosmin SPECT perfusion ima

77 e closely related to flow than were those of 99mTc-sestamibi (P < 0.001 for both comparisons).

78 tion was also less affected by flow than was 99mTc-sestamibi (P < 0.001).

79 rgically confirmed parathyroid adenomas with 99mTc-sestamibi parathyroid scans.

80 istological subtype influences positivity on 99mTc-sestamibi parathyroid scans.

81 n and scatter correction in conjunction with 99mTc sestamibi perfusion imaging.

82 strong relationship between measurements of 99mTc-sestamibi perfusion defect as measured by an autom

83 Iteratively reconstructed AC stress 99mTc-sestamibi perfusion images were compared with unco

84 99mTc-sestamibi perfusion tomography and radionuclide an

85 etate pinhole images of the neck followed by 99mTc-sestamibi pinhole images of the neck and parallel-

86 st physical examinations, were studied using 99mTc-sestamibi prone breast imaging.

87 Assessment of myocardial viability by 99mTc-sestamibi remains controversial.

88 A 99mTc-sestamibi scan demonstrated a hyperplastic parathy

89 e detectability of parathyroid adenomas with 99mTc-sestamibi scans.

90 99mTc sestamibi scintigraphy can be used to accurately q

91 dings were demonstrated by both double-phase 99mTc-sestamibi scintigraphy and MRI.

92 hese findings suggest that dobutamine stress 99mTc-sestamibi scintigraphy may underestimate the relat

93 known Pgp status, we present the findings on 99mTc-sestamibi scintigraphy of three patients with refr

94 Although dobutamine stress is used with both 99mTc sestamibi (sestamibi) myocardial perfusion imaging

95 eatment with SDZ PSC 833, scintigraphy using 99mTc-sestamibi showed normal, prompt clearance of the r

96 Rest and dipyridamole (DP)-stress 99mTc sestamibi single-photon emission computed tomograp

97 ith known or suspected CAD underwent MCE and 99mTc-sestamibi single-photon emission computed tomograp

98 early and 3-h delayed rest 201Tl SPECT, rest 99mTc-sestamibi SPECT and two-dimensional echocardiograp

99 urve analysis were performed using simulated 99mTc-sestamibi SPECT data from a population of 24 mathe

100 ection images from 8 patients who had normal 99mTc-sestamibi SPECT findings.

101 However, the use of quantitative dobutamine 99mTc-sestamibi SPECT imaging for enhanced detection of

102 l ischemia, and he was referred for a stress 99mTc-sestamibi SPECT imaging study with gating.

103 ubtraction, double-phase 99mTc-sestamibi and 99mTc-sestamibi SPECT imaging to localize abnormal parat

104 Thus, 99mTc-sestamibi SPECT imaging with gating provides infor

105 r separate, dual-isotope rest 201Tl-exercise 99mTc-sestamibi SPECT in 36 patients with <5% before-sca

106 itative visual sestamibi defect size in rest 99mTc-sestamibi SPECT in 40 consecutive patients with a

107 -sestamibi cardiac imaging, 1405 consecutive 99mTc-sestamibi SPECT myocardial perfusion studies were

108 alternative to exercise in conjunction with 99mTc-sestamibi SPECT perfusion imaging for detection of

109 We report a case in which 99mTc-sestamibi SPECT was used to localize a middle medi

110 y artery disease (CAD) before performance of 99mTc-sestamibi stress-rest myocardial perfusion SPECT.

111 lation between the results of the dual-phase 99mTc-sestamibi study and either the predominant cell ty

112 Unlike existing MDR tracers such as 99mTc-sestamibi, this compound is electroneutral, with b

113 was to determine the clinical usefulness of 99mTc-sestamibi to identify breast cancer in patients pr

114 risk zone was estimated from the severity of 99mTc-sestamibi tomographic perfusion defect.

115 Observation of 99mTc-sestamibi tumor uptake provided the impetus for it

116 01 (201Tl) at rest with rest technetium-99m (99mTc) sestamibi uptake in the same patients, using quan

117 use of only slightly delayed redistribution, 99mTc-sestamibi uptake at rest may be less than 201Tl up

118 ethod for absolute in vivo quantification of 99mTc-sestamibi uptake in a porcine model of myocardial

119 tem for quantitative in vivo measurements of 99mTc-sestamibi uptake in an animal model of myocardial

120 The z coordinate of focal 99mTc-sestamibi uptake was determined by advancing a loc

121 seen for mild 201Tl redistribution defects, 99mTc-sestamibi uptake was significantly higher than ini

122 ed in some patients focal areas of increased 99mTc-sestamibi uptake with no corresponding abnormaliti

123 99mTc sestamibi was injected intravenously just prior to

124 defects for initial 201Tl, delayed 201Tl and 99mTc-sestamibi was 62.5 +/- 2.7%, 63.1 +/- 7.1% and 67.

125 A total of 30 mCi 99mTc-sestamibi was injected at one minute into the spee

126 After administration of the Pgp modulator, 99mTc-sestamibi was selectively retained in the liver an

127 gated SPECT with 201Tl and gated SPECT with 99mTc-sestamibi was: r = 0.93 for LVEF, 0.92 for EDV, 0.

128 e relationship between 125I-iodorotenone and 99mTc-sestamibi washout was complex and depended on elap

129 properties of 64Cu-L1, 64Cu-L2, 64Cu-L3, and 99mTc-Sestamibi were evaluated in athymic nude mice bear

130 nnett's multiple comparisons test to compare 99mTc-sestamibi with initial rest 201Tl and delayed 201T